![](/sites/default/files/styles/img_search_list_desktop/public/Ratings-visual.jpg?h=d7816e94&itok=DVDA1FCo)
Standard & Poor’s has raised the outlook on the “A+” rating of SCOR SE and its main subsidiaries to “positive” as, according to S&P’s statement, “capital and earnings expected to rise due to very strong ERM”.
Standard & Poor’s has raised the outlook on the “A+” rating of SCOR SE and its main subsidiaries to “positive” as, according to S&P’s statement, “capital and earnings expected to rise due to very strong ERM”.
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
SCOR's results for the first nine months of 2013.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.